Table 3.

Incidence of clinically relevant treatment-emergent grade 3/4 laboratory abnormalities

CML-CP (n = 318)
CML-AP (n = 120)
Grades 3/4*(%)Grades 3/4*(%)
Hematologic parameters
    Thrombocytopenia2837
    Neutropenia2837§
    Anemia823
Biochemistry parameters
    Elevated lipase1517
    Hyperglycemia114
    Hypophosphatemia1010
    Elevated bilirubin (total)910
    Hypokalemia15
  • * National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.

  • CML-CP: Thrombocytopenia: 11% were grade 3, 17% were grade 4.

  • CML-AP: Thrombocytopenia: 7% were grade 3, 30% were grade 4.

  • § CML-AP: Neutropenia: 12% were grade 3, 25% were grade 4.